9 research outputs found
Natural Products for the Prevention, Treatment and Progression of Breast Cancer
In this review, we summarize the most used natural products as useful adjuvants in BC by
clarifying how these products may play a critical role in the prevention, treatment and progression of
this disease. BC is the leading cancer, in terms of incidence, that affects women. The epidemiology and
pathophysiology of BC were widely reported. Inflammation and cancer are known to influence each
other in several tumors. In the case of BC, the inflammatory component precedes the development of
the neoplasm through a slowly increasing and prolonged inflammation that also favors its growth. BC
therapy involves a multidisciplinary approach comprising surgery, radiotherapy and chemotherapy.
There are numerous observations that showed that the effects of some natural substances, which, in
integration with the classic protocols, can be used not only for prevention or integration in order to
prevent recurrences and induce a state of chemoquiescence but also as chemo- and radiosensitizers
during classic therapy
Use of Antimicrobial Irrigation and Incidence of Capsular Contracture in Breast Augmentation and Immediate Implant-Based Breast Reconstruction
Capsular contracture (CC) is one of the most common complications of implant-based breast reconstruction or augmentation surgery. Common risk factors of CC include biofilm, surgical site infections, history of prior CC or fibrosis, history of radiation therapy, and implant characteristics. Though bacterial contamination of breast protheses is associated with adverse sequelae, there are not universally accepted guidelines and limited best practice recommendations for antimicrobial breast pocket irrigation. Despite advanced molecular biology, the exact mechanism of this complication is not fully understood. Interventions that decrease the rate of CC include antibiotic prophylaxis or irrigation, acellular dermal matrix, leukotriene inhibitors, surgical techniques, and others. However, there is inconsistent evidence supporting these risk factors, and the current data was based on broad heterogeneous studies. The objective of this review was to provide a summary of the current data of contributing risk factors as well as preventative and treatment measures for CC. Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors http://www.springer.com/0026
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.
NCBINCBI Logo
Skip to main content
Skip to navigation
Resources
How To
About NCBI Accesskeys
Sign in to NCBI
PubMed
US National Library of Medicine National Institutes of Health
Search database
Search term
Clear input
Advanced
Help
Result Filters
Display Settings: Abstract
Send to:
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e30-41. doi: 10.1111/j.1468-3083.2012.04450.x. Epub 2012 Feb 7.
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.
Gisondi P1, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group.
Collaborators (368)
Author information
Abstract
OBJECTIVE:
To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks after starting a new systemic psoriasis treatment for Psocare Registry enrollees.
DESIGN:
Prospective cohort study.
SETTING:
Italian public referral centres for psoriasis treatment.
PATIENTS:
First-time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks.
MAIN OUTCOME MEASURE:
Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in serum levels (week 16) of total and low-density lipoprotein cholesterol, triglycerides, aspartate amino transferase, alanine amino transferase and creatinine, as well as week-16 cumulative incidences of new diagnoses of diabetes mellitus and arterial hypertension.
RESULTS:
Mean cholesterol and triglyceride levels significantly increased in patients treated with acitretin or cyclosporine. Mean triglyceride levels also increased in efalizumab- and etanercept-treated patients. Mean transaminase values increased in methotrexate-treated patients, and mean aspartate amino transferase levels increased in infliximab-treated patients. The average serum creatinine value increased in cyclosporine-treated patients. Acitretin and cyclosporine were associated with risk of hypercholesterolaemia (odds ratios 1.51 and 1.34) and acitretin with risk of hypertriglyceridaemia (odds ratio 1.43). Methotrexate and infliximab were associated with risk of more than doubling the upper normal aspartate amino transferase (odds ratios 2.06 and 1.87) and alanine amino transferase (odds ratios 2.38 and 1.74) values. The relative risk of developing arterial hypertension and diabetes was increased for patients receiving cyclosporine (odds ratios 3.31 and 2.88).
CONCLUSION:
Systemic treatments for psoriasis resulted in heterogeneous effects on the parameters analysed
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry
Background The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated.Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment.Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis.Results Latent tuberculosis infection was diagnosed in 8.3% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4.3% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralenultraviolet A (P < 0.05). Independent factors associated with LTBI were male sex [odds ratio (OR) 1.30, 95% confidence interval (CI) 1.04-1.62; P = 0.02], age over 55 years (OR 2.93, 95% CI 2.18-3.93; P < 0.001) and being entered into a conventional treatment (OR 3.83, 95% CI 3.10-4.74; P < 0.001). Positive history of tuberculosis was seen in 1% of patients (n = 49).Conclusions The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry
Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry
Background Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). Limitations There was a small number of patients with complete follow-up data. Conclusion PASI 75 response in patients who switched from one anti-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first anti-TNF-alfa. © 2013 by the American Academy of Dermatology, Inc
Pruritus characteristics in a large Italian cohort of psoriatic patients
none368nononeDamiani, G.; Cazzaniga, S.; Conic, R.R.Z.; Naldi, L.; Griseta, V.; Miracapillo, A.; Azzini, M.; Mocci, L.; Michelini, M.; Offidani, A.; Bernardini, L.; Campanati, A.; Ricotti, G.; Giacchetti, A.; Norat, M.; Gualco, F.; Castelli, A.; Cuccia, A.; Diana, A.; Roncarolo, G.; Belli, M.A.; Baldassarre, M.A.; Santoro, G.; Vena, G.A.; Lo Console, F.; Filotico, R.; Mastrandrea, V.; Brunetti, B.; Musumeci, F.; Carrabba, E.; Dal Mas, P.; Annicchiarico, F.; Benvegn_u, B.; Spaziani, G.; Cusano, F.; Saletta Iannazzone, S.; Galluccio, A.; Pezza, M.; Marchesi, L.; Imberti, G.; Reseghetti, A.; Barbera, C.; Reggiani, M.; Lanzoni, A.; Patrizi, A.; Bardazzi, F.; Antonucci, A.; De Tommaso, S.; Wallnofer, W.; Ingannamorte, F.; Calzavara-Pinton, P.; Iannazzi, S.; Zane, C.; Capezzera, R.; Bassisi, S.; Rossi, M.T.; Altamura, V.; Vigl, W.; Nobile, C.; Aste, N.; Murgia, S.; Mugheddu, C.; Scuderi, G.; Baglieri, F.; Di Dio, C.; Cilioni Grilli, E.; Mastronardi, C.; Agnusdei, C.P.; Antrilli, A.; Aulisa, L.; Raimondo, U.; Scotto di Luzio, G.; Battarra, V.C.; Farro, P.; Plaitano, R.; Micali, G.; Musumeci, M.L.; Massimino, D.; Li Calzi, M.; La Greca, S.; Pettinato, M.; Sapienza, G.; Valenti, G.; De Giacomo, P.F.; Amico, .; Arcangeli, F.; Brunelli, D.; Ghetti, E.; Tulli, A.; Assi, G.; Amerio, P.; Laria, G.; Prestinari, F.; Spadafora, S.; Coppola, M.; Caresana, G.; Pezzarossa, E.; Felisi, C.; Donato, L.; Bertero, M.; Musso, L.; Pa lazzini, S.; Bruscino, P.; Agozzino, U.C.; Ottaviani, M.; Simoncini, C.; Virgili, A.; Osti, F.; Fabbri, P.; Volpi, W.; Caproni, M.; Lotti, T.; Prignano, F.; Buggiani, G.; Troiano, M.; Fenizi, G.; Altobella, A.; Amoruso, A.; Condello, M.; Goffredo, A.; Righini, M.G.; Alessandrini, F.; Satolli, F.; Zampetti, M.; Bertani, E.; Fossati, S.; Parodi, A.; Burlando, M.; Fiorucci, C.; Nigro, A.; Ghigliotti, G.; Massone, L.; Moise, G.M.; Serrai, M.; Cannata, G.; Campagnoli, A.M.; Daly, M.; Leporati, C.; Peila, R.; Filosa, G.; Bugatti, L.; Nicolini, M.; Nazzari, G.; Cestari, R.; Anastasio, F.; Larussa, F.M.; Pollice, N.; De Francesco, F.; Mazzocchetti, G.; Peris, K.; Fargnoli, M.C.; Di Cesare, A.; De Angelis, L.; Flati, G.; Biamonte, A.S.; Quarta, G.; Congedo, M.; Carcaterra, A.; Strippoli, D.; Fideli, D.; Marsili, F.; Celli, M.; Ceccarini, M.; Bachini, L.; D'Oria, M.; Schirripa, V.; De Filippi, C.; Martini, P.; Lapucci, E.; Mazzatenta, C.; Ghilardi, A.; Simonacci, M.; Bettacchi, A.; Gasco, R.; Zanca, A.; Battistini, S.; Dattola, S.; Vernaci, R.; Postorino, F.; Zampieri, P.F.; Padovan, C.; Gonz_alez Intchaurraga, M.A.; Ladurner, J.; Guarneri, B.; Cannav_o, S.; Manfr_e, C.; Borgia, F.; Puglisi Guerra, A.; Cattaneo, A.; Carrera, C.; Fracchiolla, C.; Mozzanica, N.; Prezzemolo, L.; Menni, S.; Lodi, A.; Martino, P.; Monti, M.; Mancini, L.; Sacrini, F.; Altomare, G.F.; Taglioni, M.; Lovati, C.; Mercuri, S.R.; Schiesari, G.; Giannetti, A.; Conti, A.; Lasagni, C.; Greco, M.; Ronsini, G.; Schianchi, S.; Fiorentini, C.; Niglietta, S.; Maglietta, R.; Padalino, C.; Crippa, D.; Pini, M.; Rossi, E.; Tosi, D.; Armas, M.; Ruocco, V.; Ayala, F.; Balato, N.; Gaudiello, F.; Cimmino, G.F.; Monfrecola, G.; Gallo, L.; Argenziano, G.; Fulgione, E.; Berruti, G.; Ceparano, S.; De Michele, I.; Giorgiano, D.; Leigheb, G.; Deledda, S.; Peserico, A.; Alaibac, M.; Piaserico, S.; Schiesari, L.; Dan, G.; Mattei, I.; Oro, E.; Aric_o, M.; Bongiorno, M.R.; Angileri, R.; Amato, S.; Todaro, F.; Milioto, M.; Bellastro, R.; Di Nuzzo, S.; De Panfilis, G.; Zanni, M.; Borroni, G.; Cananzi, R.; Brazzelli, V.; Lisi, P.; Stingeni, L.; Hansel, K.; Pierfelice, V.; Donelli, S.; Rastelli, D.; Gasperini, M.; Barachini, P.; Cecchi, R.; Bartoli, L.; Pavesi, M.; De Paola, S.; Corradin, M.T.; Ricciuti, F.; Piccirillo, A.; Viola, L.; Tataranni, M.; Mautone, M.G.; Lo Scocco, G.; Niccoli, M.C.; Brunasso Vernetti, A.M.G.; Gaddoni, G.; Resta, F.; Casadio, M.C.; Arcidiaco, M.C.; Luvar_a, M.C.; Albertini, G.; Di Lernia, V.; Guareschi, E.; Catrani, S.; Morri, M.; Amerio, P.; De Simone, C.; D'Agostino, M.; Agostino, I.; Calvieri, S.; Cantoresi, F.; Richetta, A.; Sorgi, P.; Carnevale, C.; Nicolucci, F.; Berardesca, E.; Ardig_o, M.; De Felice, C.; Gubinelli, E.; Talamonti, M.; Camplone, G.; Cruciani, G.; Riccardi, F.; Barbati, R.; Zumiani, G.; Pagani, W.; Malagoli, P.G.; Pellicano, R.; Donadio, D.; Di Vito, C.; Cottoni, F.; Montesu, M.A.; Pirodda, C.; Addis, G.; Marongiu, P.; Farris, A.; Cacciapuoti, M.; Verrini, A.; Desirello, G.; Gnone, M.; Fimiani, M.; Pellegrino, M.; Castelli, G.; Zappal_a, L.; Sesana, G.; Ingordo, V.; Vozza, E.; Di Giuseppe, D.; Fasciocco, D.; Nespoli, P.; Papini, M.; Cicoletti, M.; Bernengo, M.G.; Ortoncelli, M.; Bonvicino, A.; Capella, G.; Doveil, G.C.; Forte, M.; Peroni, A.; Salomone, B.; Savoia, P.; Pippione, M.; Zichichi, L.; Frazzitta, M.; De Luca, G.; Zumiani, G.; Tasin, L.; Simonetto, D.; Ros, S.; Trevisan, G.; Patamia, M.; Miertusova, S.; Patrone, P.; Frattasio, A.; Piccirillo, F.; La Spina, S.; Di Gaetano, L.; Marzocchi, V.; Motolese, A.; Venturi, C.; Gai, F.; Pasquinucci, S.; Bellazzi, R.M.; Silvestri, T.; Girolomoni, G.; Gisondi, P.; Veller Fornasa, C.; Trevisan, G.P.Damiani, Giulia; Cazzaniga, S.; Conic, R. R. Z.; Naldi, L.; Griseta, V.; Miracapillo, A.; Azzini, M.; Mocci, L.; Michelini, M.; Offidani, A.; Bernardini, L.; Campanati, A.; Ricotti, G.; Giacchetti, A.; Norat, M.; Gualco, F.; Castelli, A.; Cuccia, A.; Diana, A.; Roncarolo, G.; Belli, M. A.; Baldassarre, M. A.; Santoro, G.; Vena, G. A.; Lo Console, F.; Filotico, R.; Mastrandrea, V.; Brunetti, B.; Musumeci, F.; Carrabba, E.; Dal Mas, P.; Annicchiarico, F.; Benvegn_u, B.; Spaziani, G.; Cusano, F.; Saletta Iannazzone, S.; Galluccio, A.; Pezza, M.; Marchesi, L.; Imberti, G.; Reseghetti, A.; Barbera, C.; Reggiani, M.; Lanzoni, A.; Patrizi, A.; Bardazzi, F.; Antonucci, DIEGO ADRIAN; De Tommaso, S.; Wallnofer, W.; Ingannamorte, F.; Calzavara-Pinton, P.; Iannazzi, S.; Zane, C.; Capezzera, R.; Bassisi, S.; Rossi, M. T.; Altamura, V.; Vigl, W.; Nobile, C.; Aste, N.; Murgia, S.; Mugheddu, C.; Scuderi, Gianluca; Baglieri, F.; Di Dio, C.; Cilioni Grilli, E.; Mastronardi, C.; Agnusdei, C. P.; Antrilli, A.; Aulisa, L.; Raimondo, U.; Scotto di Luzio, G.; Battarra, V. C.; Farro, P.; Plaitano, R.; Micali, G.; Musumeci, M. L.; Massimino, D.; LI CALZI, Marco; La Greca, S.; Pettinato, M.; Sapienza, G.; Valenti, G.; De Giacomo, P. F.; Amico, .; Arcangeli, F.; Brunelli, Donatella; Ghetti, E.; Tulli, A.; Assi, G.; Amerio, P.; Laria, G.; Prestinari, F.; Spadafora, S.; Coppola, M.; Caresana, G.; Pezzarossa, E.; Felisi, C.; DI DONATO, Luca; Bertero, M.; Musso, L.; Pa lazzini, S.; Bruscino, P.; Agozzino, U. C.; Ottaviani, M.; Simoncini, Claudia; Virgili, A.; Osti, F.; Fabbri, Paolo; Volpi, W.; Caproni, M.; Lotti, T.; Prignano, F.; Buggiani, G.; Troiano, M.; Fenizi, G.; Altobella, A.; Amoruso, A.; Condello, M.; Goffredo, A.; Righini, M. G.; Alessandrini, F.; Satolli, F.; Zampetti, M.; Bertani, E.; Fossati, S.; Parodi, A.; Burlando, M.; Fiorucci, C.; Nigro, A.; Ghigliotti, G.; Massone, L.; Moise, G. M.; Serrai, M.; Cannata, G.; Campagnoli, A. M.; Daly, M.; Leporati, C.; Peila, R.; Filosa, G.; Bugatti, L.; Nicolini, M.; Nazzari, G.; Cestari, R.; Anastasio, F.; Larussa, F. M.; Pollice, N.; De Francesco, F.; Mazzocchetti, Gabriele; Peris, K.; Fargnoli, M. C.; Di Cesare, A.; DE ANGELIS, Luca; Flati, G.; Biamonte, A. S.; Quarta, G.; Congedo, M.; Carcaterra, A.; Strippoli, D.; Fideli, D.; Marsili, F.; Celli, Maria; Ceccarini, M.; Bachini, L.; D'Oria, M.; Schirripa, V.; De Filippi, C.; Martini, P.; Lapucci, E.; Mazzatenta, C.; Ghilardi, A.; Simonacci, M.; Bettacchi, A.; Gasco, R.; Zanca, A.; Battistini, S.; Dattola, S.; Vernaci, R.; Postorino, F.; Zampieri, P. F.; Padovan, C.; Gonz_alez Intchaurraga, M. A.; Ladurner, J.; Guarneri, B.; Cannav_o, S.; Manfr_e, C.; Borgia, F.; Puglisi Guerra, A.; Cattaneo, A.; Carrera, C.; Fracchiolla, C.; Mozzanica, N.; Prezzemolo, L.; Menni, S.; Lodi, A.; Martino, P.; Monti, Marina; Mancini, L.; Sacrini, F.; Altomare, G. F.; Taglioni, M.; Lovati, C.; Mercuri, S. R.; Schiesari, G.; Giannetti, Anna; Conti, A.; Lasagni, C.; Greco, M.; Ronsini, G.; Schianchi, S.; Fiorentini, C.; Niglietta, S.; Maglietta, R.; Padalino, C.; Crippa, D.; Pini, M.; Rossi, E.; Tosi, D.; Armas, M.; Ruocco, V.; Ayala, F.; Balato, N.; Gaudiello, F.; Cimmino, G. F.; Monfrecola, G.; Gallo, L.; Argenziano, G.; Fulgione, E.; Berruti, G.; Ceparano, S.; De Michele, I.; Giorgiano, D.; Leigheb, G.; Deledda, S.; Peserico, A.; Alaibac, M.; Piaserico, S.; Schiesari, L.; Dan, G.; Mattei, I.; Oro, E.; Aric_o, M.; Bongiorno, M. R.; Angileri, R.; D'Amato, Sonia; Todaro, F.; Milioto, M.; Bellastro, R.; Di Nuzzo, S.; De Panfilis, G.; Zanni, M.; Borroni, Giovanni Marco; Cananzi, R.; Brazzelli, V.; Lisi, P.; Stingeni, L.; Hansel, K.; Pierfelice, V.; Donelli, S.; Rastelli, D.; Gasperini, M.; Barachini, P.; Cecchi, R.; Bartoli, L.; Pavesi, M.; De Paola, S.; Corradin, M. T.; Ricciuti, F.; Piccirillo, A.; Viola, L.; Tataranni, M.; Mautone, M. G.; Lo Scocco, G.; Niccoli, M. C.; Brunasso Vernetti, A. M. G.; Gaddoni, G.; Resta, F.; Casadio, M. C.; Arcidiaco, M. C.; Luvar_a, M. C.; Albertini, G.; Di Lernia, V.; Guareschi, E.; Catrani, S.; Morri, M.; Amerio, P.; De Simone, C.; D'Agostino, M.; Agostino, I.; Calvieri, S.; Cantoresi, F.; Richetta, A.; Sorgi, P.; Carnevale, C.; Nicolucci, F.; Berardesca, E.; Ardig_o, M.; De Felice, C.; Gubinelli, E.; Talamonti, Marco Claudio; Camplone, G.; Cruciani, G.; Riccardi, F.; Barbati, R.; Zumiani, G.; Pagani, W.; Malagoli, P. G.; Pellicano, R.; Donadio, D.; Di Vito, C.; Cottoni, F.; Montesu, M. A.; Pirodda, C.; Addis, G.; Marongiu, P.; Farris, A.; Cacciapuoti, M.; Verrini, A.; Desirello, G.; Gnone, M.; Fimiani, M.; Pellegrino, M.; Castelli, G.; Zappal_a, L.; Sesana, G.; Ingordo, V.; Vozza, E.; Di Giuseppe, D.; Fasciocco, D.; Nespoli, P.; Papini, M.; Cicoletti, M.; Bernengo, M. G.; Ortoncelli, M.; Bonvicino, A.; Capella, G.; Doveil, G. C.; Forte, M.; Peroni, A.; Salomone, B.; Savoia, P.; Pippione, M.; Zichichi, L.; Frazzitta, M.; De Luca, G.; Zumiani, G.; Tasin, L.; Simonetto, D.; Ros, S.; Trevisan, G.; Patamia, M.; Miertusova, S.; Patrone, P.; Frattasio, A.; Piccirillo, F.; La Spina, S.; Di Gaetano, L.; Marzocchi, V.; Motolese, Alfonso; Venturi, C.; Gai, F.; Pasquinucci, S.; Bellazzi, R. M.; Silvestri, T.; Girolomoni, G.; Gisondi, P.; Veller Fornasa, C.; Trevisan, G. P
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry
Objective To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks after starting a new systemic psoriasis treatment for Psocare Registry enrollees. Design Prospective cohort study. Setting Italian public referral centres for psoriasis treatment. Patients First-time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks. Main outcome measure Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in serum levels (week 16) of total and low-density lipoprotein cholesterol, triglycerides, aspartate amino transferase, alanine amino transferase and creatinine, as well as week-16 cumulative incidences of new diagnoses of diabetes mellitus and arterial hypertension. Results Mean cholesterol and triglyceride levels significantly increased in patients treated with acitretin or cyclosporine. Mean triglyceride levels also increased in efalizumab- and etanercept-treated patients. Mean transaminase values increased in methotrexate-treated patients, and mean aspartate amino transferase levels increased in infliximab-treated patients. The average serum creatinine value increased in cyclosporine-treated patients. Acitretin and cyclosporine were associated with risk of hypercholesterolaemia (odds ratios 1.51 and 1.34) and acitretin with risk of hypertriglyceridaemia (odds ratio 1.43). Methotrexate and infliximab were associated with risk of more than doubling the upper normal aspartate amino transferase (odds ratios 2.06 and 1.87) and alanine amino transferase (odds ratios 2.38 and 1.74) values. The relative risk of developing arterial hypertension and diabetes was increased for patients receiving cyclosporine (odds ratios 3.31 and 2.88). Conclusion Systemic treatments for psoriasis resulted in heterogeneous effects on the parameters analysed. \ua9 2012 European Academy of Dermatology and Venereology
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.
Objective To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks after starting a new systemic psoriasis treatment for Psocare Registry enrollees. Design Prospective cohort study. Setting Italian public referral centres for psoriasis treatment. Patients First-time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks. Main outcome measure Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in serum levels (week 16) of total and low-density lipoprotein cholesterol, triglycerides, aspartate amino transferase, alanine amino transferase and creatinine, as well as week-16 cumulative incidences of new diagnoses of diabetes mellitus and arterial hypertension. Results Mean cholesterol and triglyceride levels significantly increased in patients treated with acitretin or cyclosporine. Mean triglyceride levels also increased in efalizumab- and etanercept-treated patients. Mean transaminase values increased in methotrexate-treated patients, and mean aspartate amino transferase levels increased in infliximab-treated patients. The average serum creatinine value increased in cyclosporine-treated patients. Acitretin and cyclosporine were associated with risk of hypercholesterolaemia (odds ratios 1.51 and 1.34) and acitretin with risk of hypertriglyceridaemia (odds ratio 1.43). Methotrexate and infliximab were associated with risk of more than doubling the upper normal aspartate amino transferase (odds ratios 2.06 and 1.87) and alanine amino transferase (odds ratios 2.38 and 1.74) values. The relative risk of developing arterial hypertension and diabetes was increased for patients receiving cyclosporine (odds ratios 3.31 and 2.88). Conclusion Systemic treatments for psoriasis resulted in heterogeneous effects on the parameters analysed